Beneficial effect of JTV-803, a new synthetic inhibitor of activated factor X, against both lipopolysaccharide-induced and tissue factor-induced disseminated intravascular coagulation in rat models

Blood Coagulation and Fibrinolysis

Volumn 13, Issue 3, 2002, Pages 233-239

  Asakura, H ^a   Ichino, T ^a   Yoshida, T ^a   Suga, Y ^a   Ontachi, Y ^a   Mizutani, T ^a   Kato, M ^a   Ito, T ^a   Yamazaki, M ^a   Aoshima, K ^a   Morishita, E ^a   Saito, M ^a   Miyamoto, K I ^a   Nakao, S ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

A synthetic inhibitor of factor Xa; Disseminated intravascular coagulation; Lipopolysaccharide; Tissue factor

Indexed keywords

4 [(2 AMIDINO 1,2,3,4 TETRAHYDRO 7 ISOQUINOLINYLOXY)METHYL] 1 (4 PYRIDINYL) 4 PIPERIDINECARBOXYLIC ACID; 4 [(2 AMIDINO 1,2,3,4 TETRAHYDROISOQUINOLIN 7 YLOXY)METHYL 1 (4 PYRIDINYL)PIPERIDINE 4 CARBOXYLIC ACID]METHANESULFONATE; ANTITHROMBIN III; BLOOD CLOTTING INHIBITOR; DALTEPARIN; FACTOR X INHIBITOR; LIPOPOLYSACCHARIDE; LOW MOLECULAR WEIGHT HEPARIN; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; RAT; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ANIMALS; ANTICOAGULANTS; ANTITHROMBIN III; BIOLOGICAL MARKERS; BLOOD PROTEINS; DALTEPARIN; DISSEMINATED INTRAVASCULAR COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FACTOR X; HEMOSTASIS; ISOQUINOLINES; KIDNEY GLOMERULUS; LIPOPOLYSACCHARIDES; MALE; PIPERIDINES; PYRIDINES; RATS; RATS, WISTAR; TETRAHYDROISOQUINOLINES; THROMBOPLASTIN;

EID: 0036526497     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200204000-00009     Document Type: Article

References (35)

1. Endotoxin-induced intravascular coagulation in rabbits: Effect of tissue plasminogen activator vs. urokinase of PAI generation, fibrin deposits and mortality
2. Effect of the administration of recombinant hirudin and/or tissue plasminogen activator (t-PA) on endotoxin-induced disseminated intravascular coagulation model in rabbits
3. Diagnosis and management of disseminated intravascular coagulation: The role of heparin therapy
4. Disseminated intravascular coagulation. Approach to treatment
5. Treatment of DIC with antithrombin III concentrates
6. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation
7. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin
8. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits
9. Clinical effect of low molecular weight heparin (fragmin) on DIC: A multicenter cooperative study in Japan
10. Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC) - A multicenter co-operative double-blind trial in comparison with heparin
11. Heparin therapy in bacterial septicemia
12. Severe, acute disseminated intravascular coagulation. A reappraisal of its pathophysiology, clinical significance and therapy based on 47 patients
13. Antithrombin III (AT III) prevents LPS-induced pulmonary vascular injury: Novel biological activity of AT III
14. The anti-inflammatory properties of antithrombin III: New therapeutic implications
15. Antithrombin: Facts and new hypotheses
16. Antithrombotic effects of a synthetic inhibitor of activated factor X, JTV-803, in animals
17. Inhibitory effect of JTV-803, a new cyclic guanidine derivative, on factor Xa in vitro and in vivo
18. The prothrombin consumption time test
19. Immunological method for demonstrating fibrin degradation products in serum and its use in the diagnosis of fibrinolytic states
20. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay
21. Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats
22. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence
23. Evaluation of ready-to-use, liquid type reagents for creatinine assay 'L-type Wako Creatinine F'
24. Optimization of methods for aspartate aminotransferase and alanine aminotransferase
25. Disseminated intravascular coagulation (DIC). Immunohistochemical study of fibrin-related materials (FRMs) in renal tissues
26. The purification and mechanism of action of human antithrombin-heparin cofactor
27. Heparin like molecules with anticoagulant activity are synthesized by cultured endothelial cells
28. Role of coagulation inhibitors in inflammation
29. Antithrombin: Its physiological importance and role in DIC
30. Effect of heparin, hirudin, and a synthetic thrombin inhibitor on antithrombin III in thrombin-induced disseminated intravascular coagulation in rats
31. Influence of hirudin on the consumption of antithrombin III in experimental DIC
32. Influence of heparin and hirudin on endothelial binding of antithrombin in experimental thrombinemia
33. Disseminated intravascular coagulation
34. Thrombocytopenia in septicemia: The role of disseminated intravascular coagulation
35. Elevated platelet-associated IgG in the thrombocytopenia of septicemia